Painful Urination: Drugs That Cause It and Medications That Treat It

Painful urination, medically called dysuria, is a symptom rather than a single disease. It most often signals a bacterial urinary tract infection (UTI), but it can also come from a sexually transmitted infection, vaginal or hormonal changes, bladder pain syndrome, or a side effect of a medication the person is already taking. Nitrofurantoin (brand name Macrobid) and trimethoprim-sulfamethoxazole (Bactrim) are the antibiotics most commonly used for uncomplicated bladder infections that cause dysuria, phenazopyridine (Azo, Pyridium) is used only for short-term symptom relief, and a smaller group of drugs, including SGLT2 inhibitors such as canagliflozin, cyclophosphamide, ketamine, and some tetracyclines, are recognized causes of dysuria in their own right.

The clinical decision that matters most is not "which drug relieves the burning fastest" but whether the burning reflects an infection, a drug effect, or a non-infectious condition, because those three categories are treated in opposite ways: one calls for antibiotics, one calls for stopping or changing a medication, and one calls for local hormonal or bladder-directed therapy that antibiotics will not touch. Treating a drug-induced case as if it were an infection, or masking an infection's pain with phenazopyridine for more than a day or two, are the two most common ways this symptom gets mismanaged.

What dysuria means and why the cause matters more than the symptom

Dysuria refers to pain, burning, or discomfort during urination. It can arise from irritation anywhere along the urethra or bladder, or from inflammation in nearby structures such as the prostate or vaginal tissue. Dysuria is frequently discussed alongside UTIs because uncomplicated cystitis is thought to be the single most common identifiable cause in women, but community and outpatient studies have reported a fairly wide range of prevalence estimates for dysuria as a presenting complaint, and the exact figures depend heavily on the population studied and how symptoms were captured. Readers should treat any single percentage quoted for "how common dysuria is" as an approximation rather than a fixed fact, and any precise incidence figure used in patient materials should be checked against the original study before it is published.

Non-infectious causes are common enough that they should not be an afterthought. These include chemical irritation from soaps, spermicides, or hygiene products; atrophic vaginitis and genitourinary syndrome of menopause; interstitial cystitis/bladder pain syndrome; kidney stones; and drug-induced bladder or urethral irritation. Distinguishing between an infectious and non-infectious cause determines whether antibiotics, hormonal therapy, or simply stopping a medication is the right next step.

Medications that can cause painful urination

A short list of drugs has reasonably well-established associations with dysuria. Recognizing a drug as the cause matters clinically because the correct response is usually to modify or stop the medication in consultation with the prescriber, not to add another drug on top of it.

Cyclophosphamide and its metabolite acrolein are the best-documented cause of drug-induced bladder injury. Cyclophosphamide is used in cancer treatment and some autoimmune diseases, and its urinary metabolite can directly injure the bladder lining, producing hemorrhagic cystitis in a meaningful minority of patients receiving high-dose regimens. Co-administration of mesna and aggressive hydration is standard practice to reduce this risk; the exact incidence range varies across the oncology literature and should be confirmed against current oncology guidelines rather than a fixed percentage.

SGLT2 inhibitors (canagliflozin, dapagliflozin, empagliflozin), used for type 2 diabetes and increasingly for heart failure and chronic kidney disease, work by causing glucose to spill into the urine. That glucose-rich urine favors yeast and bacterial overgrowth. Large cardiovascular outcomes trials of this drug class, including the canagliflozin CANVAS program, reported substantially more genital mycotic infections with active drug than placebo, more so in women than men, and these infections commonly present with dysuria as the chief complaint. Exact percentage figures from that trial should be verified against the original NEJM publication before being quoted precisely; the directionally consistent finding, a clearly elevated risk of genital infection with dysuria, is well established even without a citable exact number here. The American Diabetes Association's Standards of Care advise monitoring for genitourinary symptoms in patients started on this class (ADA Standards of Care, effective for the 2022 edition; confirm against the current annual edition before citing, since ADA reissues these standards yearly).

Ketamine, used recreationally and in some off-label psychiatric settings, is associated with a well-recognized cystitis syndrome involving dysuria, urinary frequency, and reduced bladder capacity in regular users. Stopping ketamine is the only intervention consistently linked to symptom improvement, though recovery can take months and is not guaranteed to be complete after heavy or prolonged use.

Doxycycline and other tetracyclines can cause local irritation, particularly esophageal, and have been reported to contribute to urethral discomfort, especially when taken with too little water. Certain older NSAIDs, most notably tiaprofenic acid (withdrawn from several markets specifically for this reason), have been linked to chemical cystitis with dysuria and blood in the urine. Intravesical BCG therapy for bladder cancer commonly causes irritative voiding symptoms, including dysuria, that usually resolve within a day or two of each instillation.

First-line treatment when the cause is a UTI

When dysuria is due to an uncomplicated bladder infection, guideline-based antibiotic therapy is the standard approach.

Nitrofurantoin and trimethoprim-sulfamethoxazole are the two agents most consistently recommended as first-line therapy for uncomplicated cystitis by infectious disease and urology guidelines, based on their efficacy and relatively favorable resistance profiles compared with fluoroquinolones. Nitrofurantoin is avoided when kidney function is significantly reduced (commonly cited threshold: creatinine clearance below 30 mL/min) because it does not reach adequate concentrations in the urine under those conditions. Trimethoprim-sulfamethoxazole is recommended only where local resistance among common uropathogens is low enough (guidelines commonly cite a 20% local resistance threshold) and where the patient has not used it for a UTI in the preceding few months; local resistance patterns vary by region and change over time, so this determination is normally made by the prescriber or local antibiogram, not by the patient.

Fosfomycin, given as a single oral dose, is a reasonable alternative for patients who cannot tolerate first-line agents or who have a documented multidrug-resistant organism, though a randomized trial comparing single-dose fosfomycin with a five-day course of nitrofurantoin found nitrofurantoin achieved a numerically higher clinical resolution rate. The exact percentages from that trial should be confirmed against the original JAMA publication before being restated as precise figures in patient-facing material.

None of this is a substitute for individualized prescribing. The choice of antibiotic, dose, and duration depends on kidney function, allergy history, pregnancy status, local resistance patterns, and whether the infection is uncomplicated or complicated, and it should be made with a clinician rather than inferred from a general guide.

Phenazopyridine and other symptom-relief options

Phenazopyridine is a urinary tract analgesic, not an antibiotic. It relieves the burning sensation of dysuria by acting locally on the bladder and urethral lining but does nothing to treat an underlying infection. Labeling for phenazopyridine limits use to short courses (commonly two days) when taken alongside an antibiotic, because longer use is associated with methemoglobinemia, hemolytic anemia (particularly in people with G6PD deficiency), and liver injury (FDA drug label database; confirm current labeling for the specific product before quoting exact dosing). It also turns urine a harmless bright orange, which is worth mentioning to patients so they are not alarmed and so they know to remove contact lenses before it stains them.

Because phenazopyridine masks pain without treating a cause, using it beyond the labeled short course, or using it instead of seeking evaluation for infection, delays diagnosis and can allow an untreated infection to progress.

For dysuria linked to bladder spasm rather than infection, anticholinergic drugs (such as oxybutynin) or the beta-3 agonist mirabegron are sometimes used to reduce bladder overactivity and associated discomfort. These are not treatments for infectious dysuria; their role is in overactive bladder and in interstitial cystitis/bladder pain syndrome, and guideline-based care for those conditions typically starts with patient education and behavioral changes before oral medication is added.

Non-infectious dysuria: hormonal and bladder-pain causes

Not every case of dysuria responds to antibiotics, and treating it as if it were infectious when it is not exposes patients to unnecessary antimicrobial risk.

In postmenopausal women, estrogen decline thins the vaginal and urethral tissue, raises local pH, and reduces protective lactobacilli, a pattern often called genitourinary syndrome of menopause. This predisposes to both dysuria and recurrent UTI. Low-dose vaginal estrogen is generally recommended as first-line therapy for this pattern by menopause society guidance, and multiple trials have found it reduces recurrent UTI frequency, though the exact magnitude of benefit varies across studies and should not be quoted as a single fixed percentage without checking the specific meta-analysis being cited.

Interstitial cystitis/bladder pain syndrome causes chronic dysuria, pelvic pain, and urinary frequency without an identifiable infection. Pentosan polysulfate sodium (Elmiron) is the only oral medication with an FDA-approved indication specifically for this condition, but its use has been tempered in recent years by reports of pigmentary maculopathy (a retinal condition) associated with long-term, high cumulative exposure. Current urology guidance recommends discussing this risk and considering a baseline eye exam before starting the drug, and reassessing risk periodically with continued use. Anyone currently taking this medication long-term should discuss retinal screening with their prescriber rather than relying on a percentage risk quoted here.

When a medication is the identified cause, stopping or substituting it is the primary treatment. For cyclophosphamide-related cystitis, switching to an alternative agent or intensifying mesna and hydration protocols is an oncology decision, not something to change without the treating oncologist. For ketamine-associated cystitis, stopping ketamine use is the only intervention with consistent evidence of improvement, and recovery is gradual rather than immediate.

Diagnostic steps for dysuria that does not have an obvious cause

Urinalysis and urine culture are the standard first steps for evaluating dysuria. Dipstick testing for leukocyte esterase and nitrites is useful but imperfect: it can miss real infections, so a negative dipstick in someone with classic symptoms does not reliably rule out a UTI, and a culture is usually still warranted if the dipstick is negative but symptoms are convincing.

Cystoscopy, pelvic imaging, or urodynamic testing become relevant when dysuria persists for several weeks despite appropriate treatment, when blood appears in the urine, or when an anatomic abnormality is suspected. Referral to urology or urogynecology is reasonable for anyone with recurrent or refractory dysuria that does not respond to standard treatment.

Special situations that change management

Pregnancy. Asymptomatic bacteriuria in pregnancy is treated because, left untreated, it carries a meaningful risk of progressing to kidney infection (pyelonephritis), which is more dangerous in pregnancy. Guideline bodies recommend screening pregnant patients for bacteriuria early in pregnancy. Nitrofurantoin is commonly used in the second and third trimesters but has been the subject of ongoing safety discussion regarding first-trimester use and near-term use (due to a theoretical neonatal hemolysis risk at term); any antibiotic choice during pregnancy should come from the treating obstetric provider, and specific risk figures from birth-defect surveillance studies should be verified against the original research before being cited as settled numbers.

Older adults. Bacteria in the urine without symptoms is common in older adults, especially in long-term care, but current infectious disease guidance recommends against treating asymptomatic bacteriuria in non-pregnant adults, including those with urinary catheters, because treatment does not improve outcomes and contributes to antibiotic resistance. Pyuria (white cells in urine) alone, without symptoms like dysuria, urgency, or frequency, is not by itself a reason to prescribe antibiotics.

Men. Dysuria in men deserves broader evaluation than in women because uncomplicated cystitis is a less common explanation. Urethritis from a sexually transmitted infection, chronic prostatitis, and benign prostatic hyperplasia altering urine flow are all part of the differential. Current CDC STI treatment guidance addresses empiric therapy for suspected gonococcal urethritis, and any suspected STI-related dysuria warrants testing and partner-notification counseling rather than self-treatment (CDC STI Treatment Guidelines, 2021).

Reducing recurrence

For people with frequent recurrent UTIs, a few strategies have supportive evidence of varying strength. Increasing daily fluid intake has been studied in a randomized trial in premenopausal women with recurrent UTIs and was associated with fewer recurrences over a year of follow-up; the exact magnitude reported in that trial should be confirmed against the original JAMA Internal Medicine publication before being restated precisely. Cranberry products have shown inconsistent results across trials, with a recent Cochrane update finding a modest reduction in recurrence, concentrated mainly in women with a history of recurrent UTIs, rather than in the general population. Postcoital voiding is widely recommended but has not been validated in prospective trials.

For women who meet a commonly used definition of recurrent UTI (roughly two or more infections in six months, or three or more in a year), guideline-based prophylactic options include continuous low-dose nitrofurantoin, a single post-coital dose of trimethoprim-sulfamethoxazole, or patient-initiated "self-start" therapy using a pre-supplied prescription at the first sign of symptoms. Guideline authors have emphasized that the purpose of prophylaxis is to interrupt a recurrence cycle while behavioral, anatomic, or hormonal contributors are addressed, not to commit a patient to indefinite antibiotic use, and that the decision to use prophylaxis should weigh resistance risk and side effects against the burden of recurrent infection. Vaginal estrogen in postmenopausal women, methenamine hippurate, and D-mannose are non-antibiotic options with supportive but less definitive evidence than antibiotic prophylaxis.

What is established, what is plausible, and what is not settled

Established: uncomplicated bladder infections respond to short courses of nitrofurantoin or trimethoprim-sulfamethoxazole in most patients; phenazopyridine relieves dysuria symptoms but does not treat infection and carries real toxicity risk with extended use; SGLT2 inhibitors and cyclophosphamide are recognized causes of drug-induced urinary symptoms; asymptomatic bacteriuria in non-pregnant, non-catheterized older adults should not be treated with antibiotics.

Plausible but not fully settled: the exact magnitude of benefit from increased hydration, cranberry products, D-mannose, and vaginal estrogen for preventing recurrence varies across studies and populations, and effect sizes quoted from any single trial should not be generalized to all patients with dysuria. The precise incidence of dysuria in the general population is not a single agreed-upon number across the literature.

Not established here: this article does not establish an individualized diagnosis or dosing plan for any specific reader. Anyone with dysuria, especially with fever, flank pain, visible blood in the urine, inability to urinate, pregnancy, or symptoms lasting more than a day or two without improvement, needs prompt evaluation rather than self-treatment with an over-the-counter symptom reliever.

Decision framework: sorting infection, drug effect, and non-infectious causes

This is not a diagnostic tool and does not replace testing, but it can help a reader organize what to tell a clinician.

The single most consequential judgment call in this table is the second row: a reader who develops new urinary burning shortly after starting a diabetes medication, an antibiotic like doxycycline, or after ketamine exposure should raise the timing with a clinician before assuming a fresh infection, because repeated antibiotic courses for what is actually a drug effect add resistance risk and delay the fix that actually works, which is changing the medication.

When to seek urgent care

Fever, chills, flank or back pain, nausea or vomiting, visible blood in the urine, inability to urinate, or dysuria that does not improve within a day or two of starting appropriate antibiotics are reasons to seek prompt medical evaluation rather than waiting. Pregnant patients with any new urinary symptoms should contact their obstetric provider promptly given the risk of progression to kidney infection.

Where these recommendations come from, and what still needs verification

The antibiotic and prevention guidance summarized here reflects the general direction of infectious disease and urology society guidelines and commonly cited trial findings, but several specific numbers referenced in earlier drafts of this material (exact percentages for genital infection risk with SGLT2 inhibitors, exact recurrence-reduction figures for hydration, cranberry products, and vaginal estrogen, and exact retinal toxicity rates for pentosan polysulfate) could not be independently confirmed against a verified primary source during this revision and should be checked against the original trial or guideline publication before this article is finalized for publication. General regulatory and guideline references that can be verified independently include the FDA drug label database, the CDC STI treatment guidelines, and the American Diabetes Association's Standards of Care:

• FDA drug label database (accessdata.fda.gov)
• CDC Sexually Transmitted Infections Treatment Guidelines, 2021
• American Diabetes Association Standards of Care in Diabetes

Precise dosing, antibiotic choice, and duration for any individual should come from a treating clinician who has the patient's kidney function, allergy history, pregnancy status, and local resistance data, none of which this article can account for.